The results of these survival assays, especially in CD34+ stem/progenitor cells, suggest that PAK6 knockdown re-sensitizes resistant CML cells to TKI-mediated killing effects. This evidence concerns the gene PAK6 and chronic myelogenous leukemia, BCR-ABL1 positive.